WO2003074007A3 - Modulators of leukocyte activation, compositions, and methods of use - Google Patents

Modulators of leukocyte activation, compositions, and methods of use Download PDF

Info

Publication number
WO2003074007A3
WO2003074007A3 PCT/US2003/006748 US0306748W WO03074007A3 WO 2003074007 A3 WO2003074007 A3 WO 2003074007A3 US 0306748 W US0306748 W US 0306748W WO 03074007 A3 WO03074007 A3 WO 03074007A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
leukocyte activation
modulators
disorders
Prior art date
Application number
PCT/US2003/006748
Other languages
French (fr)
Other versions
WO2003074007A2 (en
Inventor
Annabelle M Friera
Marcy K Vallone
Brian Wong
Esteban Masuda
Mark Powell
Original Assignee
Rigel Pharmaceuticals Inc
Annabelle M Friera
Marcy K Vallone
Brian Wong
Esteban Masuda
Mark Powell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc, Annabelle M Friera, Marcy K Vallone, Brian Wong, Esteban Masuda, Mark Powell filed Critical Rigel Pharmaceuticals Inc
Priority to AU2003217942A priority Critical patent/AU2003217942A1/en
Publication of WO2003074007A2 publication Critical patent/WO2003074007A2/en
Publication of WO2003074007A3 publication Critical patent/WO2003074007A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides compositions and methods for modulating leukocyte activation. Nucleic acids and proteins which are capable of modulating leukocyte activation are provided. Compositions and methods for the treatment of disorders related to leukocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating leukocyte activation.
PCT/US2003/006748 2002-03-01 2003-03-03 Modulators of leukocyte activation, compositions, and methods of use WO2003074007A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003217942A AU2003217942A1 (en) 2002-03-01 2003-03-03 Modulators of leukocyte activation, compositions, and methods of use

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US36079702P 2002-03-01 2002-03-01
US36067002P 2002-03-01 2002-03-01
US36062402P 2002-03-01 2002-03-01
US36079602P 2002-03-01 2002-03-01
US36062302P 2002-03-01 2002-03-01
US60/360,670 2002-03-01
US60/360,796 2002-03-01
US60/360,797 2002-03-01
US60/360,623 2002-03-01
US60/360,624 2002-03-01
US36443702P 2002-03-15 2002-03-15
US60/364,437 2002-03-15

Publications (2)

Publication Number Publication Date
WO2003074007A2 WO2003074007A2 (en) 2003-09-12
WO2003074007A3 true WO2003074007A3 (en) 2004-10-28

Family

ID=27792375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006748 WO2003074007A2 (en) 2002-03-01 2003-03-03 Modulators of leukocyte activation, compositions, and methods of use

Country Status (2)

Country Link
AU (1) AU2003217942A1 (en)
WO (1) WO2003074007A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222276D0 (en) * 2002-09-25 2002-10-30 Inst Of Molecul & Cell Biology Methods
GB0307472D0 (en) * 2003-04-01 2003-05-07 Lorantis Ltd Medical treatment
US20090233848A1 (en) * 2004-03-09 2009-09-17 Chandra Bartholomeusz Pea15 as a Tumor Suppressor Gene
ES2327694B1 (en) * 2005-12-29 2010-10-14 Consejo Superior Investig. Cientificas SELECTIVE INHIBITORS PEPTIDES OF THE BIOLOGICAL ACTIVITY OF THE CALCINEURINE.
CN106519005B (en) * 2016-11-14 2019-12-24 深圳大学 Phosphorylated NFAT3 mutant and application thereof
EP3635402B1 (en) * 2017-05-22 2024-01-24 Edith Cowan University Biomarker of disease
EP3914726A4 (en) * 2019-01-24 2022-09-21 Council of Scientific & Industrial Research Kit for detecting melanoma
US20230020401A1 (en) * 2019-11-08 2023-01-19 Sanford Burnham Prebys Medical Discovery Institute Metabolic reprogramming of immune cells to enhance the efficacy of prophylactic and therapeutic vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WIDOM R. ET AL.: "Cloning and characterization of hcKrox, a transcriptional regulator of extracellular matrix gene expression", GENE, vol. 198, no. 1-2, 1997, pages 407 - 420, XP004570121, DOI: doi:10.1016/S0378-1119(97)00360-0 *
WIDOM R. ET AL.: "The hcKrox gene family regulates multiple extracellular matrix genes", MATRIX BIOLOGY, vol. 20, no. 7, 2001, pages 451 - 462 *

Also Published As

Publication number Publication date
WO2003074007A2 (en) 2003-09-12
AU2003217942A1 (en) 2003-09-16
AU2003217942A8 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
WO2002085285A3 (en) Methods and reagents for regulating bone and cartilage formation
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
WO2002090539A3 (en) Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
WO2004074455A3 (en) Fc REGION VARIANTS
WO2002099034A3 (en) Sequences for detection and identification of methicillin-resistant staphyloccocus aureus
WO2000006085A3 (en) Compounds and methods
WO2002038107A3 (en) Stat modulators
WO2004009559A3 (en) Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
MXPA05010277A (en) Nail polish composition and method of making same.
WO2005060542A3 (en) Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
WO2002073208A3 (en) Anti-epileptogenic agents
WO2003074007A3 (en) Modulators of leukocyte activation, compositions, and methods of use
WO2005039626A3 (en) Use of hydroxylated amino acids for treating diabetes
WO2002096348A3 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
WO2005089730A3 (en) Dna pkinase inhibitors for treating cancer and diabetes
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2004111089A3 (en) Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
WO2004009786A3 (en) Modulators of leukocyte activation, bic compositions and methods of use
WO2002062951A3 (en) Antisense modulation of casein kinase 2-alpha prime expression
DE60024997D1 (en) VGF POLYPEPTIDES AND METHOD FOR THE TREATMENT OF VGF DISEASES
WO2002079436A3 (en) Modulators of leukocyte activation, compositions and methods of use
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
WO2004004666A3 (en) Modulators of leukocyte activation, hck compositions and methods of use
WO2003020887A3 (en) Gene identification
WO2002055707A3 (en) Cloning of an inhibitor of antigen-receptor signaling by a retroviral-based functional screen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP